PDCD1 and neoplasm: PCSK9 antibodies have been reported to synergistically inhibit tumor growth with programmed cell death protein 1 (PD-1) inhibitors by promoting intratumoral infiltration of cytotoxic T cells, suggesting that PCSK9 inhibition is a feasible strategy for enhancing immune checkpoint therapy 127.